XALATAN

This brand name is authorized in Australia, Brazil, Canada, Cyprus, Germany, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Malta, Mexico, Nigeria, Netherlands, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug XALATAN contains one active pharmaceutical ingredient (API):

1 Latanoprost UNII 6Z5B6HVF6O - LATANOPROST

The active substance latanoprost, a prostaglandin F2α analogue, is a selective prostanoid FP receptor agonist which reduces the intraocular pressure (IOP) by increasing the outflow of aqueous humour. Reduction of the IOP in man starts about three to four hours after administration and maximum effect is reached after eight to twelve hours. Read about Latanoprost

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
XALATAN Eye drops, solution	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC
XALATAN Ophthalmic solution	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
S01EE01	Latanoprost	S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EE Prostaglandin analogues
Discover more medicines within S01EE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 5552F, 8243W
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 552820060069217
Country: CA	Health Products and Food Branch	Identifier(s): 02231493
Country: DE	Bundesinstitut für Arzneimittel und Medizinprodukte	Identifier(s): 00721047, 00721136, 00721219, 04385037, 04385043, 04385089, 06148169, 09537351, 09537368, 10073520, 10073537, 10073543, 10090375, 10090381, 10090398, 10218668, 10268212, 10268229, 10268235, 10710151, 10710168, 10817593, 10817618, 10817624, 11874392, 11874400, 11874417, 14018570, 15863586, 16527620
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 29697-03-11
Country: EE	Ravimiamet	Identifier(s): 1041196, 1078095
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 61756, BE183967
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 124735, 124743
Country: FR	Base de données publique des médicaments	Identifier(s): 60047271
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 13819, 139791, 147628, 164478
Country: HK	Department of Health Drug Office	Identifier(s): 42158
Country: IE	Health Products Regulatory Authority	Identifier(s): 53420, 53473
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 3815
Country: IT	Agenzia del Farmaco	Identifier(s): 033219015, 044895011, 046107013
Country: JP	医薬品医療機器総合機構	Identifier(s): 1319739Q1037
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1003206, 1082998
Country: MT	Medicines Authority	Identifier(s): MA1396/01101, PI770/15001A
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 043M98
Country: NG	Registered Drug Product Database	Identifier(s): 04-4198
Country: NL	Z-Index G-Standaard	Identifier(s): 14145332
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 48216
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100085967, 100373620
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W67251001, W67251002
Country: SG	Health Sciences Authority	Identifier(s): 09549P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 10803081, 4143011
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699759610015
Country: US	FDA, National Drug Code	Identifier(s): 0013-8303
Country: ZA	Health Products Regulatory Authority	Identifier(s): 31/15.4/0614